News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuvilex COO Highlights Advantages and Applications of Platform Cell Encapsulation Technology for Cancer, Diabetes, and Stem Cells During Recent Interview With SmallSector.com


12/18/2012 6:50:36 AM

SILVER SPRING, Md., Dec. 18, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today that major aspects of its core, "platform," cell encapsulation technology were discussed recently by Nuvilex's COO, Dr. Gerald W. Crabtree, during an interview with SmallSector.com. Advantages of Nuvilex's cell encapsulation technology, as well as its possible applications in the development of treatments for serious, debilitating, and even fatal diseases were emphasized.

Read at GlobeNewswire

comments powered by Disqus
Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES